BCCI nominates Rohit Sharma for Khel Ratna Award, Ishant, Dhawan, Deepti Sharma for Arjuna Awards | PM Cares Fund not a public authority under RTI Act, says Prime Minister's Office | India restarts economy by limiting anti-Covid lockdown to containment zones till Jun 30 | Bengal cricket team selector tests positive for Covid-19 | Centre identifies 145 new districts as potential Covid-19 hotspots |

Migraine treatment injection from Dr Reddy's Lab now available in the US

India blooms News Service | 19 Apr 2016, 08:22 pm
Hyderabad/Princeton-NJ, Apr 19 (IBNS) Promius Pharma LLC, a subsidiary of Dr. Reddy's Laboratories Ltd, has informed on Tuesday that its ZEMBRACE SymTouch (sumatriptan injection) 3 mg, which was approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the U.S.
The company said that ZEMBRACE SymTouch is a pre filled, low-dose, ready-to-use, 2-step autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. Because ZEMBRACE SymTouch is a subcutaneous injection, it may lead to rapid relief of migraine.

 

Migraineurs often have more than one kind of attack. Different types of medications can be used to treat different types of attacks. 
 
According to Roger Cady, MD, Associate Executive Chairman of the National Headache Foundation “ZEMBRACE SymTouch is a welcome addition to the toolkit for acute treatment of migraine. This 3-mg, easy to-use subcutaneous injection of sumatriptan may be desired by many migraine patients who need a medication that can rapidly treat migraine attacks. Also, the 3-mg dose allows for up to 4 doses of ZEMBRACE SymTouch in a 24-hour period, thus allowing dosing flexibility for patients.” 
 
ZEMBRACE SymTouch is available as a box of 4 autoinjectors.

Migraine treatment injection from Dr Reddy's Lab now available in the US

India blooms News Service
Comments ()

Post your comment:

Web Analytics